Visiongain Publishes Anti-infective Agents Market Report 2021-2031

27 May 2021
Pharma

Visiongain has published a new analysis of the Anti-infective Agents Market Report 2021-2031: Forecasts by Type (Antiviral Infections, Antibacterial Infections, Antifungal Infections, Others), by Route of Administration (Topical, Oral, IV, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), by Indication (Hepatitis Viral Infection, HIV Infection, Pneumonia, Aspergillosis, Methicillin-resistant Staphylococcus Aureus (MRSA), Dermatophytosis, Tuberculosis, Respiratory Virus Infection, Sepsis) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Anti-infective Agents Companies AND COVID-19 Recovery Scenarios.

The global Anti-Infective Agents market was valued at US$ US$xx bn in 2021 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Rising incidences of infectious diseases is one of the prime factors driving the growth of the global anti-infective agents market globally. Additionally, rising numbers of anti-infective agents approvals, rising research and development investments, growing healthcare awareness, and favourable government support for the development of new and innovative drugs will also support the growth of the anti-infective agents market during the same period.

How has COVID-19 had a significant negative impact on the Anti-Infective Agents Market?
The COVID-19 pandemic has a negative impact on the Anti-Infective Agents market globally. As a result of the COVID-19 outbreak, which has resulted in tight border controls, instability on the stock market, and country-wide lockdowns, this pandemic has hampered the production and distribution of Anti-Infective Agents. The question now lies in how long the effect continue.

Companies are concerned about supply and demand gaps caused by the COVID-19 epidemic. Drug production and manufacturing have traditionally been international endeavours, with China and India developing into major players in the global pharmaceutical supply chain. All of these trends are having a negative effect on the Anti-Infective Agents market, prompting industry and regulators to reconsider pharmaceutical supply chains.

How this Report Will Benefit you?
Visiongain’s report is the leading, fullest analysis this year. It has over 1125 pages - 773 tables and 816 charts/graphs. So there is nothing that comes close to this level of in-depth analysis. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global Anti-Infective Agents market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Anti-Infective Agents. Get the financial analysis of the overall market and different segments including type, route of administration, distribution channel, and indication. We believe that high opportunity remains in this fast-growing anti-infective agents market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the current market drivers?
Infectious diseases are expected to be a leading public health concern globally. Infections can be caused due to various reasons that include infections acquired from hospitals or the community. Infections are of different types as well such as viruses, bacteria, parasites, and fungi. Thus, rising incidences of infectious diseases is one of the prime factor driving the growth of the global anti-infective agents market globally.

Demographic change is increasing the demand for the anti-infective agents market. The global population is predicted to grow to 8.5 billion by 2030, up from an estimated 7.7 billion in 2019. All countries are experiencing population ageing, with the proportion of those over 65 years is projected to double between 2019 and 2050. More people live in cities and are becoming affluent, particularly in China which is experiencing the world’s fastest-ever expansion of the middle class, and whereby 2027 1.2 billion people are projected to be middle class – one-quarter of the world’s total. Thus, the rising geriatric population supports the growth of the global anti-infective agents market worldwide..

Where are the market opportunities?
Government plays an important role in the healthcare field as government allocates the funds for the healthcare sector. Additionally, government is also involved in funding research programs for critical or emergency conditions. Financial support from the government boosts the research and development efforts of various pharmaceutical companies, as this financial helps them to accelerate the development of new anti-infective agents. Thus, the favourable government support leads to rising R&D activities for newer anti-infective agents during the forecast period.

Increasing healthcare awareness and development in the healthcare infrastructure globally strengthen the anti-infective agents market in the region. The emerging economies are engaged in enhancing their healthcare infrastructure and also there is rising disposable income. This leads to an increase in the supply of medications within the country for fuelling growth. Increasing population base in the countries such as India and China with growing infectious diseases cases drive strong demand of anti-infective agents in these countries.

Competitive Landscape
The global anti-infective drugs market is a fragmented market with the presence of many global and local players operating in this market. New product launches and acquisition are some of the growth strategies adopted by the market players to enhance their presence in the global anti-infective agents market. For instance, in January 2020, Novartis acquired Medicines Company for the development of a vaccine for the treatment of infectious diseases. Some of the key players operating in the global anti-infective drugs market are GlaxoSmithKline, Alcon Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, Novartis, and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Fill-Finish Manufacturing Market Report 2021-2031

Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.

02 September 2021

Read

Visiongain Publishes Epilepsy Therapeutics Market Report 2021-2031

As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.

24 August 2021

Read

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2021-2031

From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.

24 August 2021

Read

Visiongain Publishes Bowel Management Systems Market Report 2021-2031

Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.

17 August 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever